Navigation Links
Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting

nced the reduction in tumor volume produced by cyclophosphamide and cisplatin. There was a 130 percent, 65 percent and 70 percent decrease in the tumor volume of animals administered with SPI (IRL)-1620 plus cyclophosphamide as compared to cyclophosphamide alone on day 10, 16 and 22, respectively. Similarly, the reduction in tumor volume in SPI (IRL)-1620 plus cisplatin treated animals was 31 percent, 68 percent and 80 percent greater on day 10, 16 and 22, respectively compared to cisplatin alone treated animals.

Conclusion

In conclusion, SPI (IRL)-1620 significantly enhanced the efficacy of cyclophosphamide and cisplatin in a preclinical model of ovarian tumor in mice.

About EOquin

EOquin (apaziquone for intravesical instillation) is a drug currently being developed for the treatment of non-invasive bladder cancer, which is a cancer that has invaded the inner most lining of the bladder. EOquin, an anti-cancer agent that becomes activated by reductase enzymes found in cancer cells, is formulated for administration directly into the urinary bladder. In a Phase 2 pilot study for which patient accrual was completed this year, EOquin instilled into the bladder following TUR-BT was well tolerated and was not absorbed in any detectable amount from the bladder wall into the bloodstream and therefore, would carry a low risk of harming the rest of the body.

Spectrum Pharmaceuticals completed a multi-center, Phase 2 clinical trial in Europe. The results of the trial showed that EOquin was well-tolerated and produced 67% CRs (complete responses) in patients, many of whom had been treated multiple times. EOquin received a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA) for non-invasive bladder cancer and the Company expects to begin enrollment of the first patients in the Phase 3 trial this quarter.

About Satraplatin

Satraplatin, a fourth-generation, oral investigational drug, is a member of the plati
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:8/31/2015)... , Aug. 31, 2015  Diplomat Pharmacy, Inc. (NYSE: ... announced that Phil Hagerman , Chairman & CEO, and ... investor conferences. Mr. Hagerman and Mr. Whelan ... Conference in Boston on Wednesday, September ... and Mr. Whelan are also scheduled to participate in the ...
(Date:8/31/2015)...  AMRI (NASDAQ: AMRI ) and Saneca ... on the development, manufacture and marketing of a ... collaboration combines Saneca,s strength in extracting opiates from ... manufacturing controlled substance APIs with AMRI,s U.S. assets ... these facilities. The collaboration will also capitalize on ...
(Date:8/31/2015)... 2015 Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical ... therapeutics for the treatment of diseases of the central ... BNC101 IND submission has passed review by the US ... a Phase 1 clinical trial in patients with metastatic ... prior to 31 December 2015. Bionomics, CEO ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... Jan. 26, 2011 QPS, LLC, a leading full-service ... preclinical and clinical research and development, announced the acquisition ... a full service phase 1 CRO headquartered in Hyderabad, ... QPS is a global CRO supporting drug discovery and ...
... FORT WORTH, Texas, Jan. 26, 2011 Wound Management ... an emerging leader in advanced wound care solutions, announced ... provider, Secure eHealth will be included in a technology ... Conference February 21st-24th at the Orange County Convention Center ...
Cached Medicine Technology:QPS Expands Phase 1 and Bioanalytical Capability by Acquisition of Bioserve, India 2Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase 2Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase 3Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase 4
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood Factory, ... raise money and awareness for breast and ovarian health. During September and ... Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Juvent Sports ( http://www.juvent.com ) just announced ... figures who are finding joint pain relief after using their revolutionary Micro-Impact Platform™ . ... in the world said, “For the first time in over 20 years I am ...
(Date:8/31/2015)... ... August 31, 2015 , ... Now here’s some good health ... "make at least half your grains whole,” with the majority of Americans eating more ... Whole Grains Council (WGC) released these findings and others from the 2015 Whole ...
(Date:8/31/2015)... ... August 31, 2015 , ... On Saturday, July 11, 2015, during ... in New York City, NYSATA was proud to recognize Dr. Merritt F. Spear as ... Recognition Award, named after long-time NYSATA member and Ithaca College athletic trainer and ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... All birth ... has one of the lowest failure rates among birth control methods. Moreover, no-scalpel vasectomy ... Still, some men hesitate to have their vasectomy done because they are afraid of ...
Breaking Medicine News(10 mins):Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3Health News:Most Americans Now Make Half Their Grains Whole 2Health News:Most Americans Now Make Half Their Grains Whole 3Health News:Most Americans Now Make Half Their Grains Whole 4Health News:Most Americans Now Make Half Their Grains Whole 5Health News:NYS Athletic Trainers' Association Presents Recognition Awards at Annual Conference 2Health News:NYS Athletic Trainers' Association Presents Recognition Awards at Annual Conference 3Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2
... SILVER SPRING, Md., July 6 The Obesity Society, the ... obesity, is pleased to announce the selection of Francesca M. ... Ms. Dea comes to The Obesity Society with an ... and media relations. , , According to Robert Kushner, ...
... famotidine effective at curtailing ulcers , MONDAY, July 6 (HealthDay ... in people taking low-dose aspirin, often to reduce the risk ... phase III trial included 404 patients taking 75 milligrams to ... to take either 20 milligrams of famotidine or a placebo ...
... in those with advanced chronic heart failure, have an ... to new research from researchers at the University of ... in the European Heart Journal , also suggest ... risk of death in heart failure patients, contradicting previous ...
... 6 SCAN Health Plan of Arizona has announced that ... Studios today. This partnership allows SCAN Health Plan to regularly ... and weekend shows. , , SCAN also will serve ... Gila River Casino Club 55+. This initiative is part of ...
... future of organ transplantation could include microscopic beads that ... new organ, Medical College of Georgia researchers say. ... at the MCG Center for Molecular Chaperone/Radiobiology and Cancer ... with skin grafts. The degradable microparticles deliver the ...
... Blood Types - Patients Need YOU , , NEW ... York Blood Center (NYBC) and its divisions in Manhattan, Long ... call upon the community to please give blood this month. ... of all blood types and ethnicities are encouraged to donate ...
Cached Medicine News:Health News:The Obesity Society Selects Executive Vice President 2Health News:Drug Limits Stomach Trouble in Patients Taking Low-Dose Aspirin 2Health News:Atrial fibrillation linked to increased hospitalization in heart failure patients 2Health News:Arizona's AM 1230 KOY to be Broadcast from SCAN Health Plan Studios 2Health News:Microscopic 'beads' could help create 'designer' immune cells that ignore transplanted organs 2Health News:Who Says Negatives Can't Be Positive? 2Health News:Who Says Negatives Can't Be Positive? 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: